Nuformix (LON:NFX) Posts Quarterly Earnings Results

Nuformix (LON:NFX) announced its quarterly earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Nuformix Stock Performance

Shares of LON NFX traded down GBX 0.01 ($0.00) during midday trading on Friday, reaching GBX 0.07 ($0.00). 37,799,703 shares of the company traded hands, compared to its average volume of 86,003,250. The stock has a 50-day moving average price of GBX 0.06 and a 200 day moving average price of GBX 0.10. The company has a market cap of £573,517.00, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. Nuformix has a 52 week low of GBX 0.04 ($0.00) and a 52 week high of GBX 0.34 ($0.00).

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.